TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Alaunos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.13+0.50 (+19.01%)
Close on Oct 19, 2026
- Market cap
- $7.61M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
3.6%
0M of 3M shares
Institutional holders
29
6 new, 4 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Harwin Peter Evan | 858,789 | 19.99% | 13D (active) | Oct 13, 2026 |
| PMGC Holdings Inc. | 83,500 | 5.09% | 13D (active) | May 12, 2025 |
| Postma Robert W | 514,691 | 9.99% | 13D (active) amendment | Oct 13, 2026 |
| Price Adrian | 189,061 | 8.60% | 13D (active) amendment | Feb 24, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TCRT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 21,353 | 0.84% | $48.26K | – | 0.00% |
| Geode Capital Management, LLC | 19,356 | 0.76% | $43.75K | −3,204 | 0.00% |
| Vanguard Fiduciary Trust Co | 15,497 | 0.61% | $35.02K | – | 0.00% |
| Vanguard Capital Management LLC | 14,063 | 0.55% | $31.78K | – | 0.00% |
| Citadel Advisors LLC | 11,870 | 0.47% | $26.83K | +1,351 | 0.00% |
| Osaic Holdings, Inc. | 1,731 | 0.07% | $3.91K | −48 | 0.00% |
| Tower Research Capital LLC (TRC) | 1,621 | 0.06% | $3.66K | +38 | 0.00% |
| SRS Capital Advisors, Inc. | 1,216 | 0.05% | $2.75K | New | 0.00% |
| UBS Group AG | 992 | 0.04% | $2.24K | −1,282 | 0.00% |
| Morgan Stanley | 836 | 0.03% | $1.89K | +183 | 0.00% |
| Vanguard Global Advisers, LLC | 501 | 0.02% | $1.13K | – | 0.00% |
| Wells Fargo & Company/Mn | 388 | 0.02% | $877 | +198 | 0.00% |
| Royal Bank of Canada | 375 | 0.01% | $1.00K | +190 | 0.00% |
| Ronald Blue Trust, Inc. | 135 | 0.01% | $305 | – | 0.00% |
| Steward Partners Investment Advisory, LLC | 112 | 0.00% | $253 | +20 | 0.00% |
| Federation des caisses Desjardins du Quebec | 70 | 0.00% | $158 | – | 0.00% |
| Bokf, NA | 66 | 0.00% | $149 | New | 0.00% |
| Axiom Investment Management LLC | 46 | 0.00% | $104 | New | 0.00% |
| Key Financial Inc | 24 | 0.00% | $54 | – | 0.00% |
| Signaturefd, LLC | 23 | 0.00% | $52 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 29 | 0M | 3.6% | 6 / 6 | 3 / 4 | 0M | 0M |
| Q1 2026 | 29 | 0M | 5.0% | 6 / 6 | 4 / 2 | 0M | 0M |
| Q4 2025 | 27 | 0M | 4.3% | 6 / 2 | 6 / 5 | 0M | 0M |
| Q3 2025 | 26 | 0M | 2.6% | 4 / 3 | 6 / 6 | 0M | 0M |
| Q2 2025 | 28 | 0M | 2.8% | 3 / 3 | 7 / 4 | 0M | 0M |
| Q1 2025 | 29 | 0M | 2.8% | 4 / 3 | 6 / 4 | 0M | 0M |
| Q4 2024 | 30 | 0M | 2.8% | 6 / 2 | 12 / 5 | 0M | 0M |
| Q3 2024 | 29 | 0M | 7.6% | 28 / 0 | 1 / 2 | 0M | 0M |
| Q2 2024 | 3 | 0M | 0.0% | 3 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TCRT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 15,224 | 0.60% | $44.45K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 14,063 | 0.55% | $31.78K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 2,376 | 0.09% | $6.94K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 2,317 | 0.09% | $6.77K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,117 | 0.04% | $3.26K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dale Curtis Hogue Jr. | See Remarks, Director | – | – | Apr 1, 2025 |
| Holger Weis | CEO | 44,683 | 1.76% | Aug 11, 2026 |
| Ferdinand Groenewald | Vice President of Finance | 10,775 | 0.42% | Aug 20, 2025 |
| Melinda Lackey | Legal & Administration | – | – | Apr 1, 2025 |
| Robert W. Postma | Director | 121,049 | 4.76% | Jul 27, 2026 |
| Jaime Vieser | Director | 63,245 | 2.49% | Jul 27, 2026 |
| Michael Allen Jerman | Director | 23,759 | 0.94% | Jul 27, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Holger Weis CEO | Aug 6, 2026 | Award | +4,363 | $2.01 | $8.77K | 25,483 |
| Robert W. Postma Director | Jul 23, 2026 | Award | +8,463 | $1.92 | $16.25K | 58,609 |
| Holger Weis CEO | Jul 23, 2026 | Award | +4,568 | $1.92 | $8.77K | 21,120 |
| Jaime Vieser Director | Jul 23, 2026 | Award | +8,789 | $1.92 | $16.87K | 47,642 |
| Michael Allen Jerman Director | Jul 23, 2026 | Award | +8,138 | $1.92 | $15.62K | 23,759 |
| Holger Weis Chief Executive Officer | Jun 30, 2026 | Award | +3,880 | $2.26 | $8.77K | 16,552 |
| Holger Weis Chief Executive Officer | Jun 12, 2026 | Award | +7,761 | $2.26 | $17.54K | 12,672 |
| Holger Weis Chief Executive Officer | May 22, 2026 | Award | +3,700 | $2.37 | $8.77K | 4,911 |
| Jaime Vieser Director | Apr 29, 2026 | Award | +6,515 | $2.59 | $16.87K | 38,853 |
| Michael Allen Jerman Director | Apr 29, 2026 | Award | +6,032 | $2.59 | $15.62K | 15,621 |
| Robert W. Postma Director | Apr 29, 2026 | Award | +6,274 | $2.59 | $16.25K | 50,146 |
| Michael Allen Jerman Director | Jan 12, 2026 | Award | +5,406 | $2.89 | $15.62K | 9,589 |
| Robert W. Postma Director | Jan 12, 2026 | Award | +5,622 | $2.89 | $16.25K | 43,872 |
| Jaime Vieser Director | Jan 12, 2026 | Award | +5,839 | $2.89 | $16.87K | 32,338 |
| Jaime Vieser Director | Nov 21, 2025 | Award | +5,340 | $3.16 | $16.87K | 26,499 |
| Michael Allen Jerman Director | Nov 21, 2025 | Award | +4,183 | $3.16 | $13.22K | 4,183 |
| Robert W. Postma Director | Nov 21, 2025 | Award | +5,142 | $3.16 | $16.25K | 38,250 |
| Ferdinand Groenewald Vice President of Finance | Aug 18, 2025 | Award | +10,775 | – | – | 10,775 |
| Robert W. Postma Director | Jul 3, 2025 | Award | +4,050 | – | – | 33,133 |
| Jaime Vieser Director | Jul 3, 2025 | Award | +3,400 | – | – | 21,159 |
| Robert W. Postma Director | Apr 13, 2025 | Award | +20,804 | $2.92 | $60.75K | 29,083 |
| Jaime Vieser Director | Apr 13, 2025 | Award | +17,465 | – | – | 43,359 |
| Robert W. Postma Director | Apr 13, 2025 | Award | +20,804 | $2.92 | $60.75K | 29,083 |
| Jaime Vieser Director | Dec 31, 2024 | Sale | −818 | $2.00 | $1.64K | 25,894 |
| Jaime Vieser Director | Dec 31, 2024 | Sale | −2,182 | $2.01 | $4.39K | 26,712 |
| Kevin S. Boyle Sr. Chief Executive Officer, Director | Sep 1, 2023 | Sale(10b5-1 plan) | −68,014 | $0.14 | $9.52K | 798,236 |
| Jaime Vieser Director | Nov 29, 2022 | Buy | +1,250,000 | $0.65 | $812.50K | 1,250,000 |
| Robert W. Postma Director | Nov 29, 2022 | Buy | +750,000 | $0.65 | $487.50K | 5,000,000 |
| Kevin S. Boyle Sr. Chief Executive Officer, Director | Aug 30, 2022 | Tax withholding | −18,750 | $2.41 | $45.19K | 866,250 |
| Christopher Bowden Director | Jun 22, 2022 | Award | +40,000 | – | – | 44,167 |
| James Huang Director | Jun 22, 2022 | Award | +80,000 | – | – | 188,333 |
| James Huang Director | Jun 22, 2022 | Award | +80,000 | – | – | 188,333 |
| Holger Weis Director | Jun 22, 2022 | Award | +40,000 | – | – | 160,167 |
| Robert W. Postma Director | Jun 22, 2022 | Award | +40,000 | – | – | 1,241,870 |
| Mary Thistle Director | Jun 22, 2022 | Award | +40,000 | – | – | 45,000 |
| Jaime Vieser Director | Jun 22, 2022 | Award | +40,000 | – | – | 745,321 |
| Robert W. Postma Director | Jun 22, 2022 | Award | +40,000 | – | – | 1,241,870 |
| Mary Thistle Director | Jun 22, 2022 | Award | +40,000 | – | – | 45,000 |
| Groot Eleanor De EVP, Operations | Dec 22, 2021 | Sale(10b5-1 plan) | −20,132 | $1.27 | $25.57K | 237,106 |
| Kevin S. Boyle Sr. Chief Executive Officer, Director | Nov 17, 2021 | Buy | +9,116 | $1.40 | $12.76K | 885,000 |
| Kevin S. Boyle Sr. Chief Executive Officer, Director | Nov 16, 2021 | Buy | +884 | $1.40 | $1.24K | 875,884 |
| Jaime Vieser Director | Sep 29, 2021 | Buy | +100,000 | $1.91 | $191.00K | 705,321 |
| Robert W. Postma Director | Sep 2, 2021 | Buy | +54,492 | $1.73 | $94.27K | 4,250,000 |
| Robert W. Postma Director | Sep 2, 2021 | Buy | +20,508 | $1.73 | $35.48K | 1,201,870 |
| Heidi Hagen Director | Sep 2, 2021 | Buy | +23,770 | $1.76 | $41.84K | 145,889 |
| James Huang Director | Sep 1, 2021 | Buy | +100,000 | $1.71 | $171.00K | 108,333 |
| Holger Weis Director | Sep 1, 2021 | Buy | +50,000 | $1.83 | $91.50K | 120,167 |
| Kevin S. Boyle Sr. Chief Executive Officer, Director | Aug 30, 2021 | Award | +875,000 | – | – | 875,000 |
| Raffaele Baffa Chief Medical Officer | May 17, 2021 | Award | +80,645 | – | – | 280,645 |
| J. Kevin Buchi Director | Mar 4, 2021 | Award | +4,167 | – | – | 4,167 |
| Jaime Vieser Director | Mar 4, 2021 | Award | +4,167 | – | – | 605,321 |
| James Huang Director | Mar 4, 2021 | Award | +8,333 | – | – | 8,333 |
| Holger Weis Director | Mar 4, 2021 | Award | +4,167 | – | – | 70,167 |
| Robert W. Postma Director | Mar 4, 2021 | Award | +2,500 | – | – | 1,181,362 |
| Mary Thistle Director | Mar 4, 2021 | Award | +5,000 | – | – | 5,000 |
| Christopher Bowden Director | Mar 4, 2021 | Award | +4,167 | – | – | 4,167 |
| Heidi Hagen Interim CEO, Director | Mar 4, 2021 | Award | +90,000 | – | – | 122,119 |
| Groot Eleanor De EVP, GM Cell Therapy | Mar 4, 2021 | Award | +50,825 | – | – | 257,238 |
| Robert Hadfield Chief Legal Officer and Sec. | Mar 4, 2021 | Award | +43,500 | – | – | 176,819 |
| Jill Buck EVP, GM Gene Therapy | Mar 4, 2021 | Award | +31,500 | – | – | 231,016 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jaime Vieser Director | Dec 31, 2024 | 3,000 | $6.51K | Dec 31, 2024 | Open Market Purchase |
| Kevin S. Boyle Sr. Officer | Sep 1, 2023 | 70,401 | $9.50K | Sep 1, 2023 | VESTING OF RESTRICTED STOCK |